Page 11 - WJOLS

Laparoscopic Ultrasound–Guided versus Percutaneous Radiofrequency Ablation in Treatment of Unresectable HCC

TABLE 7: Tumor marker response

Response Group I (PRFA) Group II (LUSRFA) P-value
Number 30 30
Complete response 0 8 (26.6%)
Partial response 12 (40%) 12 (40%)
Minor response 4 (13.3%) 4 (13.3%)
Stable disease 6 (6.6%) 6 (20%)
Progressive disease 8 (26.6%) 0
Overall response 16 (53.33%) 24 (80%)
Mean value (U/ml):
• Before treatment 307.47 362.8 0.033*
• After treatment 223.8 87.96
P-value 0.098 0.005
* Is significant.

TABLE 8: Late postoperative complications
Items Group I (PRFA) Group II (LUSRFA)
Initial number 20 30

Time >1-6 ms 6-12 ms 12-18 ms 18-24 ms Total >1-6 ms 6-12 ms 12-18 ms 18-24 ms Total P- value
Clinical evaluation:
1. Liver failure 4 2 2 4 12 2 0 0 0 2 0.013
2. Ascites 4 2 2 4 12 2 4 0 4 10 0.563
3. Pleural effusion 0 0 2 0 2 0 0 0 0 0 0.043
4. Varicea 2 6 4 0 12 0 4 0 0 4 0.0431
5. Tumour seedling 0 0 0 0 0 0 0 0 0 0
Deaths 4 2 2 4 12 2 4 6 0 12

TABLE 9: Local recurrence and distant metastases
Items Group I (PRFA) Group II (LUSRFA) Total P-value

Number of patients 30 30 60
Local recurrence: 8 (26.67%) 4 (13.33%) 12 (20%) 0.032
Distant Metastases: 4 (13.33%) 2 (6.67%) 6 (10%) 0.043
• Pulmonary 2 (6.67%) 2 (6.67%) 4 (6.67%)
• Bony 2 (6.67%) 0 2 (3.33%)

TABLE 10: Two years disease-free and overall survival
Items Group I (PRFA) Group II (LUSRFA) Total P- value
Number of patients 30 30 60
No. of deaths in the first month 4 (13.33%) 0 4 (6.67%)
Local recurrence 8 (26.67%) 4 (13.33%) 12 (20%) 0.032
Number of late deaths: 12 (40%) 12 (40%) 24 (40%)
• Deaths due to local recurrence 6 (20%) 2 (6.67%) 8 (13.337%)
• Deaths due to other causes 6 (20%) 10 (33.33%) 16 (26.67%)
Overall deaths 16 (53.33%) 12 (40%) 28 (46.67%) 0.045
Overall survival 14 (46.67%) 18 (60%) 32 (53.33%) 0.049
Disease free survival 12 (40%) 16 (53.33%) 28 (46.67%) 0.042

9